


## **Quick Reference Tool**



### Red Alert Management with CSAN® Pronto®

# **RED Alert**



**Product Monograph** 

ANC < 1.5 x 109/L



**(B)** 

**BEN Patient** 

ANC < 0.5 x 109/L



**Special Guidelines** 

ANC: Refer to Special Case Guidelines

1

#### 1st RED ALERT WITH CSAN® PRONTO®





Repeat a second CSAN® Pronto® test **using a new slide and sample** to confirm the results. Inadequate capillary flow, not disregarding the first two blood drops, or squeezing the patient's finger too tightly, can cause aberrant values. Note, ANC values can be lower in the morning and higher in the afternoon.



If repeat test is or continue treatment and monitor according to Product Monograph, BEN Protocol or Special Case Guidelines<sup>1</sup>.

2

#### 2<sup>nd</sup> RED ALERT WITH CSAN® PRONTO®



Immediately withhold CLOZARIL® and monitor patient closely.



Confirmation of the hematological values is recommended within 24 hours.

Have the patient return for testing with CSAN® Pronto® or a local laboratory.

2

#### CSAN® PRONTO® OR LABORATORY RESULT



or



If the result is yellow or green, continue CLOZARIL® therapy.



If the result is red, notify CSAN® at 1-800-267-2726. Available 24/7.

- Stop CLOZARIL® therapy immediately if results are confirmed.
- Blood monitoring should occur at least weekly following discontinuation of clozapine therapy until ANC is  $\geq 2.0 \times 10^9/L$  ( $\geq 1.0 \times 10^9/L$  for BEN patients), irrespective of the cause of discontinuation.
- Particular attention should be paid to any flu-like complaints or other symptoms that might suggest infection (i.e., fever, sore throat, or any other signs of infection).
- CLOZARIL<sup>®</sup> therapy must not be resumed.
- A Non-rechallengeable status is immediately assigned to the patient's profile.
- Consult with a CSAN® hematologist.

